Lenalidomide Anabiosis (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase, altering the degradation of specific transcription factors. This leads to reduced pro‑inflammatory cytokines, inhibition of new blood‑vessel formation, direct tumor‑cell apoptosis, and enhanced activity of T‑cells and natural‑killer cells.

The prescribing clinician sets the dose based on the specific indication, the patient’s renal function, prior therapies, and overall clinical status. No fixed regimen is provided here; dosing is individualized and must follow the prescriber’s instructions.

Lenalidomide is classified as Pregnancy Category X, indicating it is contraindicated in pregnancy due to proven teratogenicity. Women of child‑bearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide shares the same class (IMiD) as thalidomide and pomalidomide but generally offers a more favorable safety profile, especially regarding peripheral neuropathy. It also provides stronger anti‑angiogenic and immunomodulatory effects, making it a preferred option for many hematologic malignancies.

Store Lenalidomide Anabiosis at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid freezing.

The medication is taken orally, usually as whole tablets or capsules. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing and whether to swallow with water.

The most critical risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia or thrombocytopenia that can lead to infection or bleeding, secondary primary malignancies, and teratogenic effects that can cause birth defects.

Lenalidomide should not be used by pregnant women, individuals with uncontrolled infections, patients with severe renal impairment without dose adjustment, and those with known hypersensitivity to lenalidomide or any component of the formulation.